Clyde Biosciences, a biotechnology spinout from Glasgow University, has raised £2m ($3m) in its series A round from a consortium including Glasgow University Holdings, the university’s investment subsidiary.
Glasgow University Holdings was joined in the round by US-based venture capital firm Epidarex Capital and the Scottish Investment Bank, the investment arm of Scottish Enterprise.
Clyde Biosciences has developed technology to identify drug toxicity. It is currently developing its CellOPTIQ technology that will test for cardio-toxicity risks in new and existing…